CN101087608A - 用于治疗潜伏性结核的喹啉衍生物 - Google Patents

用于治疗潜伏性结核的喹啉衍生物 Download PDF

Info

Publication number
CN101087608A
CN101087608A CNA2005800447974A CN200580044797A CN101087608A CN 101087608 A CN101087608 A CN 101087608A CN A2005800447974 A CNA2005800447974 A CN A2005800447974A CN 200580044797 A CN200580044797 A CN 200580044797A CN 101087608 A CN101087608 A CN 101087608A
Authority
CN
China
Prior art keywords
alkyl
hydrogen
group
phenyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800447974A
Other languages
English (en)
Chinese (zh)
Inventor
K·J·L·M·安德里斯
A·考尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101087608A publication Critical patent/CN101087608A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800447974A 2004-12-24 2005-12-08 用于治疗潜伏性结核的喹啉衍生物 Pending CN101087608A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078529.7 2004-12-24
EP04078529 2004-12-24
EP05105008.6 2005-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210507318.XA Division CN103142595B (zh) 2004-12-24 2005-12-08 用于治疗潜伏性结核的喹啉衍生物

Publications (1)

Publication Number Publication Date
CN101087608A true CN101087608A (zh) 2007-12-12

Family

ID=36736133

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800447974A Pending CN101087608A (zh) 2004-12-24 2005-12-08 用于治疗潜伏性结核的喹啉衍生物

Country Status (9)

Country Link
JP (5) JP2006182755A (enExample)
KR (2) KR101301573B1 (enExample)
CN (1) CN101087608A (enExample)
BG (1) BG66437B1 (enExample)
EA (1) EA009779B1 (enExample)
ES (1) ES2362886T3 (enExample)
JO (1) JO2695B1 (enExample)
UA (1) UA88766C2 (enExample)
ZA (1) ZA200705160B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015096611A1 (zh) * 2013-12-25 2015-07-02 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
CN109069514A (zh) * 2016-03-07 2018-12-21 结核病药物开发全球联盟公司 抗菌化合物及其用途
WO2019029613A1 (zh) * 2017-08-11 2019-02-14 成都海创药业有限公司 一种氘代喹啉化合物及其制备和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015096611A1 (zh) * 2013-12-25 2015-07-02 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
CN109069514A (zh) * 2016-03-07 2018-12-21 结核病药物开发全球联盟公司 抗菌化合物及其用途
CN109069514B (zh) * 2016-03-07 2023-12-29 结核病药物开发全球联盟公司 抗菌化合物及其用途
WO2019029613A1 (zh) * 2017-08-11 2019-02-14 成都海创药业有限公司 一种氘代喹啉化合物及其制备和用途
CN109384716A (zh) * 2017-08-11 2019-02-26 成都海创药业有限公司 一种氘代喹啉化合物及其制备和用途

Also Published As

Publication number Publication date
JP2006182755A (ja) 2006-07-13
ES2362886T3 (es) 2011-07-14
JP6426530B2 (ja) 2018-11-21
ZA200705160B (en) 2008-09-25
JP2017141262A (ja) 2017-08-17
BG109180A (bg) 2006-06-30
JP2017141259A (ja) 2017-08-17
EA009779B1 (ru) 2008-04-28
KR20060073416A (ko) 2006-06-28
BG66437B1 (bg) 2014-07-31
JO2695B1 (en) 2013-03-03
KR101301573B1 (ko) 2013-09-04
JP2015157847A (ja) 2015-09-03
EA200500802A1 (ru) 2006-06-30
KR20130041872A (ko) 2013-04-25
JP2013049704A (ja) 2013-03-14
UA88766C2 (ru) 2009-11-25

Similar Documents

Publication Publication Date Title
CN103142595B (zh) 用于治疗潜伏性结核的喹啉衍生物
TWI363625B (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
TWI323730B (en) Novel mycobacterial inhibitors
JP2014132023A (ja) 医薬組成物
JP6426530B2 (ja) 潜伏性結核の処置
TWI427065B (zh) 抗菌之喹啉衍生物
HK1114006A (en) Quinoline derivatives for the treatment of latent tuberculosis
HK1186125B (en) Quinoline derivatives for the treatment of latent tuberculosis
MXPA05013413A (en) Treatment of latent tuberculosis
JP2007126452A (ja) 医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114006

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20071212

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1114006

Country of ref document: HK